{"url":"https://newsforagent.com/news/2026-10-30/annovis-bio-nyse-non-compliance-notice","markdown_url":"https://newsforagent.com/news/2026-10-30/annovis-bio-nyse-non-compliance-notice.md","title":"Annovis Bio Gets NYSE Notice Over $48.4 million Market Cap","headline":"Annovis Bio Flagged by NYSE for Market Cap and Equity Non-Compliance","description":"Annovis Bio received an NYSE notice after its 30-day average market cap fell to $48.4 million, below the $50 million threshold.","section":"Regulation & Approvals","published_at":"2026-10-30T21:18:31+00:00","modified_at":"2026-10-30T21:18:31+00:00","author":"News Desk","key_takeaways":["Annovis Bio fell below NYSE Section 802.01B with a roughly 30-day average market cap of $48.4 million and a stockholders' deficit of $4.3 million.","The company plans to submit a remediation plan within 45 days and has nine months to regain compliance if the plan is accepted.","Annovis Bio regained full NYSE continued listing compliance on May 26, 2026, after a prior non-compliance notice in March 2025."],"companies":[{"name":"Annovis Bio","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000k3r/annovis-bio","website":"http://annovisbio.com"}],"source":{"publisher":"TradingView","title":"Annovis Bio, Inc. (ANVS) Flagged by NYSE for Market Cap/Equity Non-Compliance","url":"https://www.tradingview.com/news/tradingview:bf2fd84ca62b5:0-annovis-bio-inc-anvs-flagged-by-nyse-for-market-cap-equity-non-compliance/"},"other_sources":[],"tags":["Regulation & Approvals","Annovis Bio"],"body_markdown":"[Annovis Bio](https://akta.pro/company-profiles/0000k3r/annovis-bio) received an NYSE notice that it fell below Section 802.01B, with a roughly 30-day average market cap of $48.4 million and a stockholders' deficit of $4.3 million. The company plans to submit a remediation plan within 45 days and has nine months to regain compliance, [TradingView](https://www.tradingview.com/news/tradingview:bf2fd84ca62b5:0-annovis-bio-inc-anvs-flagged-by-nyse-for-market-cap-equity-non-compliance/) reported.\n\n## Annovis Bio's NYSE Deficiency Notice\n\nAnnovis Bio is a Phase 3 clinical-stage biotechnology company developing buntanetap, an oral small molecule targeting multiple neurotoxic proteins, for patients with early Alzheimer's disease and Parkinson's disease, according to [akta.pro company records](https://akta.pro/company-data). The company is based in Malvern and was founded in 2008.\n\nThe NYSE notice cites Section 802.01B, which requires a $50 million average market cap and $50 million in stockholders' equity, according to a separate TradingView report on Accendra Health's notice. Annovis Bio's 30-day average market cap of $48.4 million sits below that threshold, and its stockholders' deficit of $4.3 million leaves equity below $50 million.\n\nThe company has 45 days to submit a remediation plan and nine months to regain compliance if the plan is accepted. A \".BC\" indicator has been added to its ticker to signal the deficiency to the market.\n\n## Annovis Bio's Prior Compliance and Funding Record\n\nAnnovis Bio regained full NYSE continued listing compliance on May 26, 2026, restoring market capitalization and stockholders' equity above the $50 million thresholds twelve months after receiving a non-compliance notice in March 2025, according to akta.pro company records. The company priced a $15.0 million underwritten public offering of 7,895,000 shares with warrants at $1.90 per share in May 2026, with Canaccord Genuity as sole bookrunner, to extend clinical development runway. Its market capitalization stood at $94.87 million in May 2026 after compliance was regained.\n\n## Alzheimer's Trial Progress Before the Notice\n\nOn October 22, 2026, Networknewsbreaks reported that Annovis Bio will present buntanetap research and Phase 3 trial updates at an Alzheimer's conference, including an oral presentation and two poster sessions, as the company approaches a pivotal clinical data readout in early 2027 and prepares for a New Drug Application. On October 5, 2026, Longevity.Technology reported that Annovis Bio partnered with Weave Bio to use AI for drafting its FDA NDA for buntanetap, with top-line Phase 3 data expected in March 2027. On September 17, 2026, AInvest reported that Annovis Bio confirmed its Alzheimer's Phase 3 trial enrolled 850 patients, exceeding the 760 target, and that its Parkinson's open-label extension study has enrolled 266 patients, with enrollment expected to finish in Q4 2026.\n\n## What Comes Next for Annovis Bio\n\nThe company's remediation plan is due within 45 days of the notice, and it has nine months to regain compliance if the plan is accepted. Top-line Phase 3 data for buntanetap is expected in March 2027, according to Longevity.Technology.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}